A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

The film gives the main points. The full list below is copied from the registry; the study team makes the final decision.

• Age18 Years to no maximum
• SexAll
• Healthy volunteersNo

You may be able to join if

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Laboratory values meeting the criteria within the protocol.
• Has measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1.

You cannot join if

• Prior systemic regimen containing c-Met targeting agent(s) (e.g., antibody, antibody drug conjugate, bispecific) and/or any topoisomerase inhibitor(s) (e.g., irinotecan).
• History of other malignancies within 5 years prior to screening, except for malignancies with a negligible risk of metastasis or death.

This is how the treatment is meant to work. Whether it helps, and how safe it is, is what this trial is testing.

Telisotuzumab. An immunoglobulin G1 (IgG1) humanized monoclonal antibody directed against human hepatocyte growth factor receptor (HGFR or c-Met), with potential antineoplastic activity. Telisotuzumab binds to c-Met, thereby preventing both c-Met binding to its ligand, HGF and the subsequent activation of the HGF/c-Met signaling pathway. This may cause cell death in c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis. NCI Drug Dictionary

Treatments listed in the registry

• Telisotuzumab Adizutecan (Drug): Intravenous (IV) Infusion
• Fluorouracil (Drug): IV Infusion; IV Injection
• Oxaliplatin (Drug): IV Infusion
• Leucovorin (Drug): IV Infusion; IV Injection
• Bevacizumab (Drug): IV Infusion
• Panitumumab (Drug): IV Infusion

Randomized · Parallel · masking: None

Main goals

• Objective Response (OR) as Assessed by the Investigator confirmed complete response (CR) or partial response (PR) as assessed by the investigator per response evaluation criteria in solid tumors (RECIST), version 1.1. (Up to 24 Weeks)
• Number of Participants with Adverse Events (AE)s (Up to Approximately 6 Years)

Other goals

• Progression-Free Survival (PFS) as Assessed by the Investigator
• Duration of Response (DOR) as Assessed by the investigator
• Overall Survival (OS)
• Disease Control (DC) as Assessed by the Investigator

Planned enrollment: 390 (estimated).

• City of Hope National Medical Center /ID# 270255, Duarte, California
• UCLA - Santa Monica /ID# 270621, Santa Monica, California
• Yale New Haven Hospital /ID# 270565, New Haven, Connecticut
• AdventHealth Orlando /ID# 270789, Orlando, Florida
• Northwest Georgia Oncology Centers /ID# 270245, Marietta, Georgia
• University of Chicago Medical Center /ID# 271688, Chicago, Illinois
• Hope And Healing Cancer Services /ID# 271562, Hinsdale, Illinois
• Dana-Farber Cancer Institute /ID# 270624, Boston, Massachusetts
• University Of Michigan /ID# 270790, Ann Arbor, Michigan
• Saint Lukes Hospital of Kansas City /ID# 270633, Kansas City, Missouri
• Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271646, Omaha, Nebraska
• University of North Carolina at Chapel Hill /ID# 267786, Chapel Hill, North Carolina
• Oncology Hematology Care - Eastgate /ID# 271493, Cincinnati, Ohio
• Texas Oncology - Austin Midtown /ID# 271354, Austin, Texas
• Texas Oncology - Deke Slayton Cancer Center /ID# 271355, Webster, Texas
• Virginia Cancer Specialists - Fairfax /ID# 271351, Fairfax, Virginia
• University Of Washington /ID# 271298, Seattle, Washington

65 recruiting sites outside the US. Site status as of Oct 30, 2026. Check the live record before contacting a site.

• ClinicalTrials.gov NCT06820463
• NCI Drug Dictionary: C184368

Registry record reviewed as fetched Oct 30, 2026, last updated by the sponsor Oct 26, 2026. Public record; not medical advice.